Related references
Note: Only part of the references are listed.Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
Julian R. Levell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Stefan Pusch et al.
ACTA NEUROPATHOLOGICA (2017)
Highly predictive and interpretable models for PAMPA permeability
Hongmao Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Michael M. Gottesman et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies
Daniel Martinez Molina et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays
Mindy I. Davis et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2016)
Avoiding Fluorescence Assay InterferenceThe Case for Diaphorase
Matthew D. Hall et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2016)
Cancer anabolic metabolism inhibitors move into clinic
Ken Garber
NATURE BIOTECHNOLOGY (2016)
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice
Zhenyue Hao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Supriya K. Saha et al.
CANCER DISCOVERY (2016)
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Johanna Mondesir et al.
JOURNAL OF BLOOD MEDICINE (2016)
An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software
Pranav Shah et al.
DRUG METABOLISM AND DISPOSITION (2016)
Evaluating Potential P-gp Substrates: Main Aspects to Choose the Adequate Permeability Model for Assessing Gastrointestinal Drug Absorption
Joao Batista da Silva Junior et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2015)
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Ujunwa C. Okoye-Okafor et al.
NATURE CHEMICAL BIOLOGY (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Tackling reproducibility in academic preclinical drug discovery
Stephen V. Frye et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Luyuan Li et al.
PLOS ONE (2015)
Spherical Cancer Models in Tumor Biology
Louis-Bastien Weiswald et al.
NEOPLASIA (2015)
Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule
Gejing Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Genglin Jin et al.
Oncotarget (2015)
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
Remco J. Molenaar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
Mindy I. Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The cellular thermal shift assay for evaluating drug target interactions in cells
Rozbeh Jafari et al.
NATURE PROTOCOLS (2014)
A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Adnan Elhammali et al.
CANCER DISCOVERY (2014)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
Lenny Dang et al.
NATURE (2010)
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
K. E. Yen et al.
ONCOGENE (2010)
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel
Steven A. Titus et al.
ANALYTICAL BIOCHEMISTRY (2009)
Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications
P. Kannan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
In Vitro Solubility Assays in Drug Discovery
Edward H. Kerns et al.
CURRENT DRUG METABOLISM (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells
Noboru Uchide et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Drugs as materials:: Valuing physical form in drug discovery
CR Gardner et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Multicellular resistance: a paradigm for clinical resistance?
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2000)
Share Paper
